San Diego-primarily based Viking Therapeutics marked itself as a significant competitor from the weight loss drug market in February just after revealing promising knowledge from the mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection As well as in M